Terminated early: drug combo test for tough cancer halted
NCT ID NCT05921760
Summary
This early-stage study aimed to test the safety and initial effectiveness of a three-drug combination for people with advanced bile duct cancer that has a specific genetic change (IDH1 mutation). The treatment combined a targeted drug (ivosidenib) with two immunotherapy drugs. The trial was stopped early by the sponsor after enrolling only 7 people, so no results on effectiveness are available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH1-MUTANT CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore, Maryland, 21231, United States
-
UCLH
London, NW1 2PG, United Kingdom
-
UCSF - Medical Center at Mission Bay
San Francisco, California, 94158, United States
-
Ucsf Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.